公开(公告)号：KR1020120095170A

公开(公告)日：2012-08-28

申请号：KR1020110014674

申请日：2011-02-18

Applicant: 충남대학교산학협력단

Inventor： 조은경 ,  최흥식 ,  육재민

IPC: A61K31/216 ,  A61K31/215 ,  A61P31/00

CPC classification number: A61K31/216

Abstract: PURPOSE: A pharmaceutical composition containing fenofibrate for preventing septicemia is provided to suppress secretion of cytokine and drastically increase survival rate. CONSTITUTION: A pharmaceutical composition for preventing septicemia containes fenofibrate as an active ingredient. The sepsis is caused by infection of the gram-negative bacteria. The fenofibrate is formed into a formulation of powder, granule, tablet, capsule or injection by mixing with a pharmaceutically allowed carrier, a forming agent, and diluent. The fenobrate dose is 1-100mg per 1kg per day and is divided into 1 time-several times to be administrated.

Abstract translation: 目的：提供含有非诺贝特预防败血症的药物组合物，以抑制细胞因子的分泌，大大提高存活率。 构成：用于预防败血症的药物组合物含有非诺贝特作为活性成分。 败血症是由革兰氏阴性细菌感染引起的。 通过与药学上允许的载体，成形剂和稀释剂混合，将非诺贝特形成为粉末，颗粒，片剂，胶囊或注射剂的制剂。 fenobrate剂量为每天1kg 1-100mg，分1次给药。

公开(公告)号：KR1020100050198A

公开(公告)日：2010-05-13

申请号：KR1020080109371

申请日：2008-11-05

Applicant: 충남대학교산학협력단

Inventor： 전병화 ,  조은경 ,  육재민

IPC: A61K38/16 ,  A61P35/00

CPC classification number: A61K38/1793 ,  C07K14/4713 ,  C07K2319/00

Abstract: PURPOSE: A pharmaceutical composition containing tat-ret-1 fusion protein is provided to effectively prevent and treat autoimmune diseases and cancer by controlling the development of HMGB1(high-mobility group box 1). CONSTITUTION: A pharmaceutical composition for treating autoimmune diseases and cancer contains tat-ref-1 fusion protein with the sequence number 1 as an active ingredient. The Tat-ref-1 fusion protein is produced by E.coli transformant BL 21(DE3)/pTat-ref-1 transformed as a development vector. The autoimmune disease includes sepsis, Churg-Strauss syndrome, Sjogren's syndrome, Systemic lupus erythematosus, or Rheumatoid arthritis. The cancer includes breast cancer, colon cancer, melanoma, prostate cancer, lung cancer or pancreatic cancer. The amount of each dose is 0.1~10 nM per day.

Abstract translation: 目的：提供含有tat-ret-1融合蛋白的药物组合物，通过控制HMGB1（高迁移率组盒1）的发展来有效预防和治疗自身免疫性疾病和癌症。 构成：用于治疗自身免疫疾病和癌症的药物组合物含有序列号1的tat-ref-1融合蛋白作为活性成分。 Tat-ref-1融合蛋白由作为显影载体转化的大肠杆菌转化株BL21（DE3）/ pTat-ref-1产生。 自身免疫性疾病包括败血症，Churg-Strauss综合征，干燥综合征，系统性红斑狼疮或类风湿关节炎。 癌症包括乳腺癌，结肠癌，黑素瘤，前列腺癌，肺癌或胰腺癌。 每剂量为0.1〜10nM /天。